Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells

Blood Cells, Molecules, and Diseases

Volumn 51, Issue 3, 2013, Pages 177-184

  Cui, Xue Yan ^a,b,c   Skretting, Grethe ^c,d   Jing, Ying ^b   Sun, Hui ^a   Sandset, Per Morten ^c,d,e   Sun, Ling ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Hypoxia; Leukemia; Multi drug resistance; Stem cell like properties

Indexed keywords

2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; CYTARABINE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; METHOTREXATE; OCTAMER TRANSCRIPTION FACTOR 4; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE;

ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN K 562; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEM CELL; UPREGULATION; WESTERN BLOTTING;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5- DIPHENYLTETRAZOLIUM BROMIDE; ABC; ACUTE MYELOID LEUKEMIA; AML; ARA-C; ATP-BINDING CASSETTE; BM; BONE MARROW; CYTOSINE ARABINOSIDE; DIMETHYL SULFOXIDE; DMSO; DOX; DOXORUBICIN; DRUG CONCENTRATIONS INHIBITING CELL GROWTH BY 50%; HYPOXIA; IC(50); LEUKEMIA; MDR; METHOTREXATE; MTT; MTX; MULTI-DRUG RESISTANCE; MULTI-DRUG RESISTANT; PAGE; POLYACRYLAMIDE GEL ELECTROPHORESIS; STEM CELL-LIKE PROPERTIES; TBS-T; TGF-Β; TRANSFORMING GROWTH FACTOR-Β; TRIS-BUFFERED SALINE-TWEEN; VCR; VINCRISTINE;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84881030198     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.05.003     Document Type: Article

References (55)

1. Appelbaum F.R., Gundacker H., Head D.R., Slovak M.L., Willman C.L., Godwin J.E., Anderson J.E., Petersdorf S.H. Age and acute myeloid leukemia. Blood 2006, 107(9):3481-3485.
2. Gottesman M.M. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1993, 53(4):747-754.
3. Kaspers G.J., Veerman A.J. Clinical significance of cellular drug resistance in childhood leukemia. Recent Results Cancer Res. 2003, 161:196-220.
4. Stavrovskaya A.A., Stromskaya T.P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 2008, 73(5):592-604.
5. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(26):15665-15670.
6. Ross D.D., Karp J.E., Chen T.T., Doyle L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000, 96(1):365-368.
7. Benderra Z., Faussat A.M., Sayada L., Perrot J.Y., Chaoui D., Marie J.P., Legrand O. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 2004, 10(23):7896-7902.
8. Bunting K.D. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002, 20(1):11-20.
9. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7(9):1028-1034.
10. Grant J.L., Smith B. Bone marrow gas tensions, bone marrow blood flow, and erythropoiesis in man. Ann. Intern. Med. 1963, 58:801-809.
11. D'Ippolito G., Diabira S., Howard G.A., Roos B.A., Schiller P.C. Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells. Bone 2006, 39(3):513-522.
12. Eliasson P., Jonsson J.I. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J. Cell. Physiol. 2010, 222(1):17-22.
13. Snyder C.M., Chandel N.S. Mitochondrial regulation of cell survival and death during low-oxygen conditions. Antioxid. Redox Signal. 2009, 11(11):2673-2683.
14. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359(6398):843-845.
15. Mohyeldin A., Garzon-Muvdi T., Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7(2):150-161.
16. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111.
17. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(8):2784-2789.
18. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425(6958):577-584.
19. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113(6):685-700.
20. Mishra L., Derynck R., Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005, 310(5745):68-71.
21. Zhang H., Akman H.O., Smith E.L., Zhao J., Murphy-Ullrich J.E., Batuman O.A. Cellular response to hypoxia involves signaling via Smad proteins. Blood 2003, 101(6):2253-2260.
22. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncology 2005, 7(2):134-153.
23. Tsuruo T., Iida-Saito H., Kawabata H., Oh-hara T., Hamada H., Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn. J. Cancer Res. 1986, 77(7):682-692.
24. Price P., McMillan T.J. Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Res. 1990, 50(5):1392-1396.
25. Sargent J.M. The use of the MTT assay to study drug resistance in fresh tumour samples. Recent Results Cancer Res. 2003, 161:13-25.
26. Seo S.B., Hur J.G., Kim M.J., Lee J.W., Kim H.B., Bae J.H., Kim D.W., Kang C.D., Kim S.H. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol. Cancer 2010, 9:199.
27. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., Akiyama T., Kuroda H., Kawano Y., Kobune M., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 2003, 9(9):1158-1165.
28. Simon M.C., Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat. Rev. Mol. Cell Biol. 2008, 9(4):285-296.
29. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
30. Natarajan K., Xie Y., Baer M.R., Ross D.D. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem. Pharmacol. 2012, 83(8):1084-1103.
31. Chow D.C., Wenning L.A., Miller W.M., Papoutsakis E.T. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophys. J. 2001, 81(2):675-684.
32. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2(1):38-47.
33. Roberts A.M., Watson I.R., Evans A.J., Foster D.A., Irwin M.S., Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res. 2009, 69(23):9056-9064.
34. Xiang L., Liu Z.H., Huan Q., Su P., Du G.J., Wang Y., Gao P., Zhou G.Y. Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma. Diagn. Pathol. 2012, 7:32.
35. Shin D.M., Jeon J.H., Kim C.W., Cho S.Y., Kwon J.C., Lee H.J., Choi K.H., Park S.C., Kim I.G. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutaminase 2 in age-related cataractogenesis. J. Biol. Chem. 2004, 279(15):15032-15039.
36. Jang G.Y., Jeon J.H., Cho S.Y., Shin D.M., Kim C.W., Jeong E.M., Bae H.C., Kim T.W., Lee S.H., Choi Y., et al. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2010, 29(3):356-367.
37. Cho S.Y., Jeong E.M., Lee J.H., Kim H.J., Lim J., Kim C.W., Shin D.M., Jeon J.H., Choi K., Kim I.G. Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death. Mol. Cells 2012, 33(3):235-241.
38. Filiano A.J., Tucholski J., Dolan P.J., Colak G., Johnson G.V. Transglutaminase 2 protects against ischemic stroke. Neurobiol. Dis. 2010, 39(3):334-343.
39. Niwa H., Miyazaki J., Smith A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 2000, 24(4):372-376.
40. Kumar S.M., Liu S., Lu H., Zhang H., Zhang P.J., Gimotty P.A., Guerra M., Guo W., Xu X. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012, 31(47):4898-4911.
41. Dvorak P., Hampl A. Basic fibroblast growth factor and its receptors in human embryonic stem cells. Folia Histochem. Cytobiol. 2005, 43(4):203-208.
42. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2(4):333-344.
43. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40(5):499-507.
44. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., Gritti A., Piccinini A., Porro D., Santinami M., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43(5):935-946.
45. Tirino V., Desiderio V., d'Aquino R., De Francesco F., Pirozzi G., Graziano A., Galderisi U., Cavaliere C., De Rosa A., Papaccio G., et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008, 3(10):e3469.
46. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., Zheng B.J., Guan X.Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132(7):2542-2556.
47. Shmelkov S.V., Meeus S., Moussazadeh N., Kermani P., Rashbaum W.K., Rabbany S.Y., Hanson M.A., Lane W.J., St Clair R., Walsh K.A., et al. Cytokine preconditioning promotes codifferentiation of human fetal liver CD133+ stem cells into angiomyogenic tissue. Circulation 2005, 111(9):1175-1183.
48. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1(4):389-402.
49. Baba T., Convery P.A., Matsumura N., Whitaker R.S., Kondoh E., Perry T., Huang Z., Bentley R.C., Mori S., Fujii S., et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28(2):209-218.
50. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., Pratesi G., Fabbri A., Andriani F., Tinelli S., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(38):16281-16286.
51. Gallacher L., Murdoch B., Wu D.M., Karanu F.N., Keeney M., Bhatia M. Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 2000, 95(9):2813-2820.
52. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(6464):645-648.
53. Eisterer W., Jiang X., Christ O., Glimm H., Lee K.H., Pang E., Lambie K., Shaw G., Holyoake T.L., Petzer A.L., et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005, 19(3):435-441.
54. Kolenda J., Jensen S.S., Aaberg-Jessen C., Christensen K., Andersen C., Brunner N., Kristensen B.W. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J. Neurooncol. 2011, 103(1):43-58.
55. Schiller M., Javelaud D., Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J. Dermatol. Sci. 2004, 35(2):83-92.